From the University of California San Diego, La Jolla, California; and.
Allergy Asthma Proc. 2020 Nov 1;41(Suppl 1):S26-S29. doi: 10.2500/aap.2020.41.200066.
The availability of effective acute treatment for angioedema has been fundamental in reducing the burden of illness for patients with hereditary angioedema (HAE). In building on the foundation of scientific advances that elucidate the pathomechanism(s) of attacks related to vascular permeability, novel targeted on-demand treatments have been developed and approved. These therapies have provided the means to arrest episodes of swelling, which, in the past, had the potential to inexorably lead to morbidity, and even mortality, for patients with HAE. Access to these medications, along with an emphasis on early administration and guidance that all attacks are candidates for treatment, has shifted the management paradigm for HAE. Although unmet needs remain, these acute therapies, coupled with advances in prophylactic treatment, have furthered the goal for all patients with HAE to live a normal life.
有效的急性治疗药物的出现，对于减轻遗传性血管性水肿（HAE）患者的疾病负担至关重要。在阐明与血管通透性相关的攻击病理机制的科学进步基础上，新型靶向按需治疗药物已经开发并获得批准。这些疗法为阻止肿胀发作提供了手段，过去，这些发作有可能不可避免地导致 HAE 患者出现发病率，甚至死亡率。获得这些药物，以及强调早期给药和指导，即所有发作都有治疗的可能，这已经改变了 HAE 的治疗模式。尽管仍存在未满足的需求，但这些急性治疗药物，加上预防性治疗的进展，进一步推动了 HAE 所有患者过上正常生活的目标。
